Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Drug for an 'undruggable' protein

Scientists have long aimed to develop drugs against the cancer-associated protein KRAS, but without success. An approach that targets the oncoprotein's cellular localization reignites lost enthusiasm. See Letter p.638

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    *This article and the paper under discussion2 were published online on 22 May 2013.


  1. 1

    Cox, A. D. & Der, C. J. Small GTPases 1, 2–27 (2010).

    Article  Google Scholar 

  2. 2

    Zimmermann, G. et al. Nature 497, 638–642 (2013).

    ADS  CAS  Article  Google Scholar 

  3. 3

    Berndt, N., Hamilton, A. D. & Sebti, S. M. Nature Rev. Cancer 11, 775–791 (2011).

    CAS  Article  Google Scholar 

  4. 4

    Ahearn, I. M., Haigis, K., Bar-Sagi, D. & Philips, M. R. Nature Rev. Mol. Cell Biol. 13, 39–51 (2012).

    CAS  Article  Google Scholar 

  5. 5

    Philips, M. R. Nature Cell Biol. 14, 128–129 (2012).

    CAS  Article  Google Scholar 

  6. 6

    Nancy, V., Callebaut, I., El Marjou, A. & de Gunzburg, J. J. Biol. Chem. 277, 15076–15084 (2002).

    CAS  Article  Google Scholar 

  7. 7

    Ismail, S. A. et al. Nature Chem. Biol. 7, 942–949 (2011).

    CAS  Article  Google Scholar 

  8. 8

    Chandra, A. et al. Nature Cell Biol. 14, 148–158 (2012).

    CAS  Article  Google Scholar 

  9. 9

    Zhang, H. et al. Proc. Natl Acad. Sci. USA 104, 8857–8862 (2007).

    ADS  CAS  Article  Google Scholar 

  10. 10

    Laheru, D. et al. Invest. New Drugs 30, 2391–2399 (2012).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Channing J. Der.

Ethics declarations

Competing interests

C.J.D. has received honoraria from Bristol-Myers Squibb, Eli Lilly and Merck, and has a research contract with GlaxoSmithKline.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baker, N., Der, C. Drug for an 'undruggable' protein. Nature 497, 577–578 (2013).

Download citation

Further reading


Quick links